In silico and in vitro analyses of a novel FoxO1 agonist reducing Aβ levels via downregulation of BACE1
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14140 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Ming-Ti Lv und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroblastoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Henan, Key Scientific Research Project of Higher Education of Henan Province.
Abstract (Originalsprache)
Aims
FoxO1 is an important target in the treatment of Alzheimer's disease (AD). However, FoxO1‐specific agonists and their effects on AD have not yet been reported. This study aimed to identify small molecules that upregulate the activity of FoxO1 to attenuate the symptoms of AD.
Methods
FoxO1 agonists were identified by in silico screening and molecular dynamics simulation. Western blotting and reverse transcription‐quantitative polymerase chain reaction assays were used to assess protein and gene expression levels of P21, BIM, and PPARγ downstream of FoxO1 in SH‐SY5Y cells, respectively. Western blotting and enzyme‐linked immunoassays were performed to explore the effect of FoxO1 agonists on APP metabolism.
Results
N‐(3‐methylisothiazol‐5‐yl)‐2‐(2‐oxobenzo[d]oxazol‐3(2H)‐yl) acetamide (compound D) had the highest affinity for FoxO1. Compound D activated FoxO1 and regulated the expression of its downstream target genes, P21 , BIM , and PPARγ . In SH‐SY5Y cells treated with compound D, BACE1 expression levels were downregulated, and the levels of Aβ 1‐40 and Aβ 1‐42 were also reduced.
Conclusions
We present a novel small‐molecule FoxO1 agonist with good anti‐AD effects. This study highlights a promising strategy for new drug discovery for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
- School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
- School of Medical Technology, Xinxiang Medical University, Xinxiang, China.
- School of Pharmacy, Xinxiang Medical University, Xinxiang, China.
- School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
ORCID-Profile: Ming-Ti Lv, Wei Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Henan
- Key Scientific Research Project of Higher Education of Henan Province
- The Open Fund of Henan Key lab of Biological Psychiatry
Zitieren
APA
Lv, M. T., Wang, H. C., Meng, X. W., Shi, Y. T., Zhang, Y. M., Shan, L. L., Shi, R. L., Ni, T. J., Duan, Y. C., Yang, Z. J., & Zhang, W. (2024). In silico and in vitro analyses of a novel FoxO1 agonist reducing Aβ levels via downregulation of BACE1. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14140
Vancouver
Lv MT, Wang HC, Meng XW, Shi YT, Zhang YM, Shan LL, et al. In silico and in vitro analyses of a novel FoxO1 agonist reducing Aβ levels via downregulation of BACE1. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14140
BibTeX
@article{Lv2024,
author = {Lv, Ming-Ti and Wang, He-Cheng and Meng, Xiao-Wen and Shi, Ya-Ting and Zhang, Yi-Min and Shan, Lin-Lin and Shi, Ru-Ling and Ni, Tian-Jun and Duan, Ying-Chao and Yang, Zhi-Jun and Zhang, Wei},
title = {In silico and in vitro analyses of a novel FoxO1 agonist reducing Aβ levels via downregulation of BACE1},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14140}
}
EUVIMED